BIVI Latest Press Releases

-- October 26, 2026 --

BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop Globe Newswire 8:00 AM

-- October 20, 2026 --

BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting Globe Newswire 8:00 AM

-- October 19, 2026 --

BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting Globe Newswire 8:00 AM

-- October 14, 2026 --

BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting Globe Newswire 8:00 AM

-- September 15, 2026 --

BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Globe Newswire 7:30 AM

-- September 14, 2026 --

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid Globe Newswire 4:01 PM

-- September 8, 2026 --

BioVie Announces Update to Parkinson's Phase 3 Development Program Globe Newswire 7:30 AM

-- August 31, 2026 --

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Globe Newswire 8:00 AM

-- August 6, 2026 --

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease Globe Newswire 7:30 AM

-- June 5, 2026 --

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 3:31 PM

Market Data Delayed 15 Minutes